Baseline demographics and clinical characteristics by LOT
| Characteristic . | Previously untreated n = 855 . | R/R n = 607 . |
|---|---|---|
| Median age (range), y | 70 (37-95) | 72 (34-95) |
| Sex, n (%) | ||
| Male | 547 (64) | 392 (65) |
| Female | 308 (36) | 215 (35) |
| Race, n (%) | ||
| White | 780 (91) | 545 (90) |
| African American | 58 (7) | 48 (8) |
| Asian | 2 (<1) | 4 (<1) |
| American Indian or Alaskan Native | 3 (<1) | 1 (<1) |
| Other | 1 (<1) | 1 (<1) |
| Unknown/not available | 11 (1) | 8 (1) |
| Institution type, number of sites (%) | ||
| Community∗ | 156 (94) | 138 (93) |
| Academic | 10 (6) | 10 (7) |
| Institution type, number of patients, n (%) | ||
| Community∗ | 806 (94) | 553 (91) |
| Academic | 49 (6) | 54 (9) |
| US regions, n (%) | ||
| South | 414 (48) | 286 (47) |
| Midwest | 172 (20) | 119 (20) |
| Northeast | 131 (15) | 110 (18) |
| West | 138 (16) | 92 (15) |
| Insurance, n (%)† | ||
| Public‡ | 601 (70) | 473 (78) |
| Private§ | 329 (38) | 217 (36) |
| None | 8 (1) | 2 (<1) |
| Other‖ | 7 (1) | 4 (1) |
| ECOG status, n/N (%)‖ | ||
| 0 | 393/823 (48) | 271/580 (47) |
| 1 | 375/823 (46) | 247/580 (43) |
| ≥2 | 55/823 (7) | 62/580 (11) |
| Rai staging done at enrollment, n (%) | ||
| Yes | 547 (64) | 305 (50) |
| No | 262 (31) | 256 (42) |
| Missing/not specified | 46 (5) | 46 (8) |
| Rai stage at enrollment, n/N (%)¶ | ||
| Stage IV | 133/547 (24) | 111/305 (36) |
| Stage III | 125/547 (23) | 63/305 (21) |
| Stage II | 105/547 (19) | 47/305 (15) |
| Stage I | 111/547 (20) | 48/305 (16) |
| Stage 0 | 66/547 (12) | 25/305 (8) |
| CCI, median (range) | 1 (0-11) | 1 (0-8) |
| Most common comorbidities, n (%)# | ||
| Hypertension | 552 (65) | 384 (63) |
| Diabetes mellitus | 206 (24) | 134 (22) |
| Arthropathies | 181 (21) | 108 (18) |
| COPD/pulmonary disease | 152 (18) | 122 (20) |
| Thyroid disorders | 138 (16) | 92 (15) |
| Ischemic heart disease | 135 (16) | 79 (13) |
| Cardiac arrhythmia | 104 (12) | 91 (15) |
| Atrial fibrillation | 68 (8) | 64 (11) |
| Chronic kidney disease | 81 (10) | 59 (10) |
| Peripheral vascular disease | 70 (8) | 61 (10) |
| History of previous malignancies | 196 (23) | 172 (28) |
| Median follow-up (range), mo | 14.9 (0.03-46.9) | 15.3 (0.03-44.0) |
| Characteristic . | Previously untreated n = 855 . | R/R n = 607 . |
|---|---|---|
| Median age (range), y | 70 (37-95) | 72 (34-95) |
| Sex, n (%) | ||
| Male | 547 (64) | 392 (65) |
| Female | 308 (36) | 215 (35) |
| Race, n (%) | ||
| White | 780 (91) | 545 (90) |
| African American | 58 (7) | 48 (8) |
| Asian | 2 (<1) | 4 (<1) |
| American Indian or Alaskan Native | 3 (<1) | 1 (<1) |
| Other | 1 (<1) | 1 (<1) |
| Unknown/not available | 11 (1) | 8 (1) |
| Institution type, number of sites (%) | ||
| Community∗ | 156 (94) | 138 (93) |
| Academic | 10 (6) | 10 (7) |
| Institution type, number of patients, n (%) | ||
| Community∗ | 806 (94) | 553 (91) |
| Academic | 49 (6) | 54 (9) |
| US regions, n (%) | ||
| South | 414 (48) | 286 (47) |
| Midwest | 172 (20) | 119 (20) |
| Northeast | 131 (15) | 110 (18) |
| West | 138 (16) | 92 (15) |
| Insurance, n (%)† | ||
| Public‡ | 601 (70) | 473 (78) |
| Private§ | 329 (38) | 217 (36) |
| None | 8 (1) | 2 (<1) |
| Other‖ | 7 (1) | 4 (1) |
| ECOG status, n/N (%)‖ | ||
| 0 | 393/823 (48) | 271/580 (47) |
| 1 | 375/823 (46) | 247/580 (43) |
| ≥2 | 55/823 (7) | 62/580 (11) |
| Rai staging done at enrollment, n (%) | ||
| Yes | 547 (64) | 305 (50) |
| No | 262 (31) | 256 (42) |
| Missing/not specified | 46 (5) | 46 (8) |
| Rai stage at enrollment, n/N (%)¶ | ||
| Stage IV | 133/547 (24) | 111/305 (36) |
| Stage III | 125/547 (23) | 63/305 (21) |
| Stage II | 105/547 (19) | 47/305 (15) |
| Stage I | 111/547 (20) | 48/305 (16) |
| Stage 0 | 66/547 (12) | 25/305 (8) |
| CCI, median (range) | 1 (0-11) | 1 (0-8) |
| Most common comorbidities, n (%)# | ||
| Hypertension | 552 (65) | 384 (63) |
| Diabetes mellitus | 206 (24) | 134 (22) |
| Arthropathies | 181 (21) | 108 (18) |
| COPD/pulmonary disease | 152 (18) | 122 (20) |
| Thyroid disorders | 138 (16) | 92 (15) |
| Ischemic heart disease | 135 (16) | 79 (13) |
| Cardiac arrhythmia | 104 (12) | 91 (15) |
| Atrial fibrillation | 68 (8) | 64 (11) |
| Chronic kidney disease | 81 (10) | 59 (10) |
| Peripheral vascular disease | 70 (8) | 61 (10) |
| History of previous malignancies | 196 (23) | 172 (28) |
| Median follow-up (range), mo | 14.9 (0.03-46.9) | 15.3 (0.03-44.0) |
CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; LOT, line of therapy.
Centers not affiliated with teaching/academic institutions.
Patients may have had both private and public insurance; therefore, the sum of the total may be more than 100%.
Includes employer-based, American Association of Retired Persons, self-pay, private insurance, and exchange-based coverage (through the Health Insurance Marketplace or state-based exchanges that were established as part of the Affordable Care Act of 2010), and other.
Includes Medicare, Medicaid, and military-based.
Both private and public insurance.
Percent reported among patients with staging information available.
Most common comorbidities defined as those reported in ≥8% of overall patient population.